-
Arsenal crowned Premier League champions after Man City draw
-
New York art auctions roar back with blockbuster sales
-
US says held talks with Cuba on $100 mln offer
-
Chelsea beat Spurs to leave rivals in 'embarrassing' relegation danger
-
Google wants its search bar to act on your behalf in AI revamp
-
Taiwan author wins International Booker for 'slyly sophisticated' novel
-
Iran 'very confident' about World Cup protocols: federation vice-president
-
Google unveils smart glasses, taking on Meta
-
Guardiola swerves Man City exit talk as title hopes ended
-
Chiefs' Rice jailed for probation violation
-
Five factors in Arsenal's Premier League title triumph
-
Mikel Arteta: Pep protege to Premier League winner
-
How Arsenal banished 'nearly men' tag to end 22-year title wait
-
Arsenal win Premier League after Man City held by Bournemouth
-
From graduation boos to voter unease: AI anxiety grows in the US
-
Lost in Trump's climate boast: best-case scenario abandoned
-
Hantavirus cruise operator says ship not source of outbreak
-
Trump shows off ballroom site with 'drone empire' planned for roof
-
Rubio to attend NATO talks, pay first visit to India
-
Under Trump pressure, EU seeks deal to end trade standoff
-
Airbus seeks to cut peripheral expenses due to Mideast war
-
France encourages women to report rape in probes of star Bruel
-
Guardiola silent on Man City exit reports
-
Argentine researchers collect rodents for hantavirus tests
-
Iran talks making 'good progress': US VP Vance
-
Teen wonder Sooryavanshi's slams 93 to edge Rajasthan closer to IPL play-offs
-
Norway reports Europe's first case of bird flu in a polar bear
-
Italy's Ganna wins time-trial in Giro shake-up
-
EU vows help for farmers hit by Iran war fertiliser price hikes
-
Emery focused on Villa glory, not crown of Europa League 'king'
-
French govt slams 'disproportionate' Canal+ riposte to anti-Bollore petition
-
US, Iran trade threats but Trump says Tehran wants peace deal
-
Russia's Zvyagintsev sets film amid 'disaster' Ukraine war
-
UK trade minister hopes Britain will rejoin EU 'in my lifetime'
-
Race to find vaccines, treatments for Ebola strain behind outbreak
-
King Charles III bangs drum for Irish music, eyes hip-hop lesson
-
Ganna wins time-trial in Giro shake-up
-
Drone attack kills 28 at market in southern Sudan
-
Putin lands in China for trip that aims to show unshakeable ties after Trump pomp
-
Israel finance minister says ICC seeks arrest warrant against him
-
Kentucky primary vote tests Trump's grip on Republican base
-
Alcaraz withdraws from Wimbledon with wrist injury
-
Indie game plunges players into sci-fi epic 'Battlestar Galactica'
-
Trump shows off site of new $400-mn ballroom
-
Israeli troops in Iraq: what do we know?
-
Iran warns against new US attacks as Trump says held off assault
-
Oil dips, stocks mixed after Trump holds off on Iran attack
-
India rest Bumrah for one-off Test against Afghanistan
-
G7 finance ministers vow cooperation to face 'heightened risks'
-
Ghana, Ivory Coast to clash in 2027 AFCON qualifying
UK researchers cure man who had Covid for 411 days
British researchers announced Friday they have cured a man who was continually infected with Covid for 411 days by analysing the genetic code of his particular virus to find the right treatment.
Persistent Covid infection -- which is different to long Covid or repeated bouts of the disease -- occurs in a small number of patients with already weakened immune systems.
These patients can test positive for months or even years with the infection "rumbling along the whole time", said Luke Snell, a physician specialising in infectious diseases at Guy's and St Thomas' NHS Foundation Trust.
The infections can pose a serious threat because around half of patients also have persistent symptoms such as lung inflammation, Snell told AFP, adding that much remains unknown about the condition.
In a new study published in the journal Clinical Infectious Diseases, a team of researchers at Guy's and St Thomas' NHS Foundation Trust and King's College London describe how a 59-year-old man finally overcame his infection after more than 13 months.
The man, who has a weakened immune system due to a kidney transplant, caught Covid in December 2020 and continued to test positive until January this year.
To discover whether he had contracted Covid numerous times or if it was one persistent infection, the researchers used a rapid genetic analysis with nanopore sequencing technology.
The test, which can deliver results in as little as 24 hours, showed the man had an early B.1 variant which was dominant in late 2020 but has since been replaced by newer strains.
Because he had this early variant, the researchers gave him a combination of the casirivimab and imdevimab monoclonal antibodies from Regeneron.
Like most other antibody treatments, the treatment is no longer widely used because it is ineffective against newer variants such as Omicron.
But it successfully cured the man because he was battling a variant from an earlier phase of the pandemic.
- Resistant to treatment -
"The very new variants that are increasing in prevalence now are resistant to all the antibodies available in the UK, the EU and now even the US," Snell said.
The researchers used several such treatments to try to save a seriously ill 60-year-old man in August this year who had been infected since April.
However none worked.
"We really thought he was going to die," Snell said.
So the team crushed up two antiviral treatments not previously used together -- Paxlovid and remdesivir -- and administered them to the unconscious patient via a nasal tube, according to a non-peer-reviewed preprint study on the website ResearchSquare.
"Miraculously he cleared and perhaps this is now the avenue for how we treat these very difficult persistent infections," Snell said, emphasising that this treatment may not translate for normal Covid cases.
At the ECCMID conference in April, the team announced the longest-known persistent infection in a man who tested positive for 505 days before his death.
That "very sad case" came earlier in the pandemic, Snell said, adding that he was grateful there were now so many more treatment options available.
N.Shalabi--SF-PST